STAT3 and B-cell non-Hodgkin lymphoma: As shown in Figures 1C and 1D, silencing Stat3 through locally delivered CpG-Stat3 siRNA significantly enhanced the antitumor efficacies of systemic administration of PD-1- and CTLA4-specific antibodies in mice bearing the A20 B cell lymphoma arresting tumor growth.